Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A ginsenoside composition capable of preventing and treating alcoholic fatty liver

A kind of technology of alcoholic fatty liver and ginsenoside, applied in the field of biomedicine

Active Publication Date: 2021-07-02
SHAANXI GIANT BIOTECHNOLOGY CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have reported that ginsenosides Rk3 and Rh4 have obvious anti-tumor, anti-oxidation, anti-inflammatory, and anti-apoptotic effects. There are also literature reports that ginsenosides CK, Rh1 and their compositions can be used to improve non-alcoholic fatty liver disease. Fibrosis and insulin resistance drugs, but no research on alcoholic fatty liver; ginsenoside Rg1 has a certain effect on the treatment of metabolic disorders caused by drinking, but whether it has a protective effect on the liver has not been studied, while ginsenoside Rk3 / Rh4 Combination drugs have never been used to improve fatty liver, liver disease and reduction of liver antioxidant substances caused by alcohol

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A ginsenoside composition capable of preventing and treating alcoholic fatty liver
  • A ginsenoside composition capable of preventing and treating alcoholic fatty liver
  • A ginsenoside composition capable of preventing and treating alcoholic fatty liver

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1 Preparation of Tablets with Ginsenoside Rk3 / Rh4 Composition for Prevention and Treatment of Alcoholic Fatty Liver

[0068] Take 100g of ginsenoside Rk3 with a purity of ≥98%, 200g of ginsenoside Rh4 with a purity of ≥98%, and 500g of pharmaceutical excipients commonly used in the preparation of tablets, mix them evenly, compress them into tablets, dry, and pack to obtain 2000 tablets of the present invention , Each tablet contains 150mg of active ingredients.

Embodiment 2

[0069] Example 2 Preparation of Capsules with Ginsenoside Rk3 / Rh4 Composition for Prevention and Treatment of Alcoholic Fatty Liver

[0070] Get 100g of ginsenoside Rk3 with a purity of ≥98%, 100g of ginsenoside Rh4 with a purity of ≥98%, and 600g of commonly used pharmaceutical adjuvants, mix evenly, and then pack into capsules currently on the market to obtain 2000 capsules of the present invention. The active ingredient content in each capsule is 100mg.

Embodiment 3

[0071] Example 3 Preparation of Ginsenoside Rk3 / Rh4 Composition Oral Liquid for Prevention and Treatment of Alcoholic Fatty Liver

[0072] Take 40g of ginsenoside Rk3 with a purity of ≥98%, and 80g of ginsenoside Rh4 with a purity of ≥98%, mix them evenly, then add appropriate amount of flavoring agent crystalline fructose, stachyose, citric acid, pectin, diluent water, and heat Dissolve, homogeneously fill, sterilize, make 1000 bottles of oral liquid of the present invention, contain active ingredient 120mg in every bottle of oral liquid.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a ginsenoside composition capable of preventing and treating alcoholic fatty liver. The pharmaceutical composition of the present invention that can be used for the prevention and / or treatment of alcoholic fatty liver comprises a preventive and / or therapeutic effective amount of ginsenoside Rk3 and ginsenoside Rh4 as active ingredients, and a pharmaceutically acceptable carrier, the pharmaceutical composition wherein, the weight ratio of ginsenoside Rk3 to ginsenoside Rh4 is 1:0.5-2, preferably 1:0.9-1.1. The ginsenoside composition of the invention can obviously improve the abnormal liver function index caused by heavy drinking, and reduce the inflammatory infiltration of liver tissue and the generation of fat vacuoles. The present invention provides a synergistic pharmaceutical composition comprising ginsenosides Rk3 and Rh4, capable of preventing and / or treating alcoholic fatty liver.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a ginsenoside Rk3 / Rh4 composition capable of preventing and treating alcoholic fatty liver. Background technique [0002] Fatty liver disease is a common disease, which can be divided into alcoholic fatty liver disease (alcoholic fatty liver, AFL) and non-alcoholic fatty liver disease (NAFLD) according to the history of heavy drinking. The main causes of damage are the toxic metabolites produced by the metabolism of alcohol in liver cells, oxidative stress and the metabolic disorders caused by it. The pathogenesis of NAFLD is mainly related to IR, abnormal liver fat metabolism, mitochondrial dysfunction and oxidative stress, genetic variation and metabolic changes, and susceptibility to cell damage. Although various liver diseases caused by viral hepatitis occupy a major position, with the rise of alcohol in the human diet structure, the incidence of alcoholic fatty liver is getting h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/704A61P1/16
CPCA61K31/704A61P1/16A61K2300/00
Inventor 范代娣贺婧段志广马晓轩
Owner SHAANXI GIANT BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com